Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F23%3A10465130" target="_blank" >RIV/00216208:11130/23:10465130 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/23:10465130

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=cIXfeVawb1" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=cIXfeVawb1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fphar.2023.1178009" target="_blank" >10.3389/fphar.2023.1178009</a>

Result language

angličtina

Original language name

Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study

Original language description

Introduction: Seminal clinical trials with the triple combination of elexacaftor-tezacaftor-ivacaftor (ETI) demonstrated clinical efficacy in people with cystic fibrosis (pwCF) who carry at least one F508del mutation. However, due to exclusion criteria of these clinical trials, the effect of ETI was not studied in a substantial number of pwCF. Thus, we ran a single center trial to evaluate a clinical efficacy of ETI treatment in adult pwCF who were ineligible for enrollment in registration studies. Methods: PwCF on ETI with prior lumacaftor-ivacaftor therapy, severe airway obstruction, well-preserved lung function, or with airway infection with pathogens at risk of more rapid decline in lung function formed the study group, while all the others on ETI formed the control group. Lung function, nutritional status and sweat chloride concentration were assessed before and after initialization of ETI therapy over a 6-month period. Results: Approximately a half of the ETI-treated pwCF at the adult Prague CF center (49 of 96) were assigned to the study group. Their mean changes in body mass index ( + 1.04 kg/m(2)) and in sweat chloride concentration (-48.4 mmol/L) were similar to the control group ( + 1.02 kg/m(2); -49.7 mmol/L), while the mean change in percent predicted forced expiratory volume in 1 s (ppFEV(1); + 10.3 points) was significantly lower than in the control group ( + 15.8 points) (p = 0.0015). In the subgroup analysis, pwCF with severe airway obstruction (ppFEV(1) &lt;40) and pwCF with well-preserved lung function (ppFEV(1) &gt;90) showed a less potential for improvement in lung function during the ETI treatment than controls (median change in ppFEV(1) + 4.9 points and + 9.5 points, respectively). Conclusion: PwCF not eligible for inclusion in clinical trials demonstrated improvement in lung function and nutritional status following the initiation of treatment with the ETI combination. Moderate increase in ppFEV(1) was observed in those with severe airway obstruction or well-preserved lung function.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30203 - Respiratory systems

Project

<a href="/en/project/NU20-07-00049" target="_blank" >NU20-07-00049: Intestinal organoids as an in-vitro model for predicting the response to therapies correcting molecular defects in cystic fibrosis</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in Pharmacology

ISSN

1663-9812

e-ISSN

—

Volume of the periodical

14

Issue of the periodical within the volume

June

Country of publishing house

CH - SWITZERLAND

Number of pages

7

Pages from-to

1178009

UT code for WoS article

001011385500001

EID of the result in the Scopus database

2-s2.0-85162084503